The use of epoetin beta in anemic predialysis patients with chronic renal failure
Koch, K.M.; Koene, R.A.; Messinger, D.; Quarder, O.; Scigalla, P.
Clinical Nephrology 44(3): 201-208
1995
ISSN/ISBN: 0301-0430 PMID: 8556837 Document Number: 454822
Two clinical studies were conducted to investigate the efficacy and safety of epoetin beta in 26 anemic predialysis patients. Epoetin beta was administered subcutaneously either daily or thrice weekly. Mean duration of treatment was 211 days (interquartile range: 105 to 350 days). Results: Renal anemia could be corrected and the regular transfusion need could be eliminated in all patients. There was no difference in the dose requirement per week between daily and thrice weekly administration of epoetin beta. Regarding the entire study population, there was no acceleration of the progression of renal failure during epoetin beta treatment nor were there any notable changes in laboratory values other than retention values. Epoetin beta was safe and well tolerated; the most important adverse event was the development or aggravation of hypertension.